Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
18 Sep, 26
ERS 2026
Key updates on asthma presented at ERS 2026 at Barcelona, Spain from 5th - 9th September, 2026.
18 Sep, 26
ERS 2026
Key updates on respiratory infections presented at ERS 2026 at Barcelona, Spain from 5th - 9th September, 2026.
28 Sep, 26
Obesity Med.
- Of the 833 adults in India with HTN &/or DM attending an NCD clinic, 70.7% had clinical obesity, highest in HTN alone (88%), with significantly elevated BMI & Conicity Index
- Clinical obesity was independently linked with age 60-69 yrs, extended family, HTN duration >10 yrs, tobacco use, & coexistence of HTN+DM
- Sensitivity analysis showed a lower obesity burden (50%) but retained significant predictor links.
25 Sep, 26
J. Cos. Dermatol.
- In this randomized trial, 156 subjects received a novel HA-based injection or established HA filler for moderate-to-severe horizontal neck wrinkles
- At wk 4, ≥1-point improvement on the Allergan Transverse Neck Lines Scale was achieved in 83.3% vs 71.8% of patients (difference: 11.54%)
- The novel HA filler demonstrated non-inferior efficacy, with comparable safety & no serious adverse events reported.
24 Sep, 26
Cardiovasc Diabetol.
- Among 6023 adults with CKM stages 0-3, 399 developed CMM in 9 yrs
- Each 1-SD rise in TyG-FI, CTI-FI, CHG-FI, & SHR-FI raised CMM risk by 27-31% (HR 1.27-1.31), while higher eGDR/FI cut risk by 39% (HR 0.61)
- Concurrent insulin resistance & frailty conferred greatest risk, with CHG+FI (HR 6.47) & CTI+FI (HR 6.27)
- An integrated insulin resistance-frailty assessment may improve early CMM stratification (AUC: 0.742)
23 Sep, 26
Am J Respir Crit Car...
- Among 99,748 adults with mild-to-moderate asthma after a first exacerbation, 4.1% developed severe asthma within 5 years
- Risk factors included age 40–49 years, exacerbation despite medium-dose ICS, high SABA use, recurrent respiratory infections, and eosinophils ≥0.6×10⁹/L
- High-risk patients with late-onset eosinophilic asthma and recurrent infections had a 30.4% progression risk, supporting early identification.
22 Sep, 26
Featured

28 Sep, 26

28 Sep, 26

28 Sep, 26
















